#EULAR2022 OP0273 Difficult to treat RA (D2TRA): ⭐️Lower socioeconomic treatment ⭐️RF positivity ⭐️Higher inflammatory markers ⭐️ILD ⭐️Lower proportion on MTX, better response to JAKi and RTX @RheumNow

Was ORAL Surveillance really a surprise? Let's look post-hoc at all the other tofacitinib RCTs (ph 1-3b/4 +LTE) Cardiovascular risk-enriched pts were always in the same MACE ballpark with tofa ORAL Surveillance was worse, but clues were always there OP0264 #EULAR2022 @RheumNow https://t.co/rB5SwVX2oc

GLORIA trial presented by Martin Boxers. 2 yr RCT, 5mg Pred vs. PBO shows DAS28 benefit (-0.37 to -0.62) & -1.7 better X-ray (vs PBO) at 2yrs. BUT signif more harm (AE) RR 1.24; mostly infx. Is this a good trade off? Abst# OP0263 #EULAR2022 https://t.co/kBiRYxXXZe

#OP0247 #EULAR2022 Prof Mease analysed US Database (>1 million) pre- & post-Omicron using machine learning.Factors assoc with poor #COVID outcomes in IMID:age & comorbidities. Vaccination was protective. JAK-I and RTX increased risk weakly initially but not post-Omicron @RheumNow https://t.co/JCqTZvPgll

Risk of haematological malignancy in PsA Nordic cohorts *40 events, IR 67/100 000 person-years *NO difference between PsA bionaive and TNFi treated BUT *⬆️ in PsA vs. matched controls *no difference between myeloid and lymphoid malignancies. OP0257 #EULAR2022 @RheumNow https://t.co/oIojobgDP3

Swedish study by Lindstrom U et al of over 3000 PsA patients matched with RA comparators showed that the length of time on MTX (PsA 4.5 and RA 4.4 years) before adding or switching to b/tsDMARD was identical in PsA (34%) and matched RA controls (33%) #EULAR2022 @RheumNow POS0073 https://t.co/Dwrz8RVMnh

Can genetics solve all the world's problems with predicting response to therapy in rheumatology? No - but maybe it can be a part of the solution? Multi-domain apporaches (including good clinical data) needed to really have cut-through @karolinskainst OP0267 #EULAR2022 @RheumNow https://t.co/wISPUB6m64

#OP0248 #EULAR2022 In contrast to data from #OP0247 where SpA was protective, a matched population study in Canada found the opposite - increased risk of hospitalisation & death in SpA. A meta-analysis cd help to disentangle this @RheumNow https://t.co/keNZ2RPnXF

New Tool! STAR (#Sjogren’s Tool for Assessing Response) was developed to assess treatment response in primary Sjogren’s and will be validated on 3 datasets #EULAR2022 @rheumnow OP0286 https://t.co/9tgVSWGxEc

Izokibep Phase 2 in active PsA at Wk 16 results (80mg dose): ⭐️ACR50 52% ⭐️PASI 90 50% ⭐️Resolution of enthesitis LEI 88% ⭐️Safety profile similar to what observed in PsO. Promising for the enthesitis domain! @RheumNow OP0258 #EULAR2022 https://t.co/Wm3MvVQzoP

Dr Singh @NamrataRheum et al. VA study of lymphoma risk with b/tsDMARDs. No increased risk found. HR adjusted time-fixed and time-varying covariates vs csDMARD 1.04 (0.80-1.35) @RheumNow #EULAR2022 POS1434 https://t.co/B6ENz805yl

#OP0251 #EULAR2022 Any data to support association of RA-ILD with poor #COVID outcomes? A study is US >500 pts (9% ILD) showed ILD as well as poor RA status (RF+ & erosion) increased risk. Detailed analysis inc Radiographic + PFT cd help stratify risk further @RheumNow https://t.co/E89dd38GQS

#EULAR2022 OP0276: What do patients want for preventative interventions for RA? ⭐️Survey of 1st degree relatives of RA pts (at risk) vs general pop were similar ⭐️'Hypothetical' treatment profile best aligned to abatacept @Rheumnow https://t.co/r4y7SZbjTA

Montastruc et al. VigiBase study of CV and VTE events in JAKi vs TNFi. >270000 events. DECREASE in MACE ROR=0.87 [95%CI 0.80-0.95]. INCREASE in DVT: ROR=3.99 [3.15-5.04], PE: ROR=3.47 [2.90-4.13] @RheumNow #EULAR2022 OP0268 https://t.co/lUin7ciXWt https://t.co/Gr4Kvd8F7R

• EULAR Abstract Archive

Survival of RA-ILD pts w/ lung 🫁 transplantation Retrospective single centre study *Mortality 36% *Usual Interstitial Pneumonia worst prognosis w/ HR 7.13 (did not reach significance, small cohort) *Survival time comparable to other lung Tx cohorts #EULAR2022 OP0275 @RheumNow https://t.co/LslPxyXJCp